← Leaderboards
Deyu Fang
Northwestern University
$18,368,021
Attributed
$27,663,977
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,663,977 · 14
By mechanism
R01$24,153,297 · 10
DP2$2,385,148 · 1
R21$739,282 · 2
R56$386,250 · 1
Top collaborators
- Kezhong Zhang9 shared
- Ling Qi7 shared
- Huiping Liu5 shared
- Bin Zhang5 shared
- Qing-Sheng Mi3 shared
- Li Zhou3 shared
Most similar at Northwestern University
Same institution · by research overlap
- David D McPherson$77,387,749
- Gary E Schiltz$5,645,620
- Martin F Jarrold$2,053,550
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMediatingProteinsCellsTranscription FactorBasePlayGenetic TranscriptionPathway InteractionsProductionKnockout MiceT-LymphocyteAffectMouse ModelAutoimmune DiseasesPeripheralCytokineTherapeutic TargetAmericanT-Cell ActivationImmune ResponseAutoimmune ProcessRegulationHomeostasis
Grant awards (58)
VPS72 controls Treg cell stability and adaptation to tumor microenvironment$1,843,396
R01 · FY2025 · CA
Novel role of hepatic SEL1L-HRD1 ERAD in bile acid metabolism$700,085
R01 · FY2025 · DK
Clinical analysis and therapeutic development of exosomal ACE2$697,517
R01 · FY2025 · AI
Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancer$661,072
R01 · FY2025 · CA · contact PI
A deubiquitination module controls Treg adaptation to tumor microenvironment$560,370
R01 · FY2025 · CA · contact PI
Clinical analysis and therapeutic development of exosomal ACE2$697,517
R01 · FY2024 · AI
Novel role of hepatic SEL1L-HRD1 ERAD in bile acid metabolism$696,090
R01 · FY2024 · DK
VPS72 controls Treg cell stability and adaptation to tumor microenvironment$602,346
R01 · FY2024 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment$533,802
R01 · FY2024 · CA · contact PI
Regulation of Rhythmic m6A RNA Modification by ERâassociated Degradation$503,374
R01 · FY2024 · DK
Clinical analysis and therapeutic development of exosomal ACE2$748,517
R01 · FY2023 · AI
Novel Role of Hepatic SEL1L-HRD1 ERAD in Bile Acid Metabolism$700,434
R01 · FY2023 · DK
VPS72 controls Treg cell stability and adaptation to tumor microenvironment$658,092
R01 · FY2023 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment$552,115
R01 · FY2023 · CA · contact PI
Regulation of Rhythmic m6A RNA Modification by ERâassociated Degradation$549,099
R01 · FY2023 · DK
Clinical analysis and therapeutic development of exosomal ACE2$779,400
R01 · FY2022 · AI
Regulation of Rhythmic m6A RNA Modification by ERâassociated Degradation$558,588
R01 · FY2022 · DK
A deubiquitination module controls Treg adaptation to tumor microenvironment$553,526
R01 · FY2022 · CA · contact PI
Targeting a Treg deubiquitinase in antitumor immune therapy$345,141
R01 · FY2022 · CA · contact PI
Regulation of Rhythmic m6A RNA Modification by ERâassociated Degradation$574,804
R01 · FY2021 · DK
A deubiquitination module controls Treg adaptation to tumor microenvironment$561,629
R01 · FY2021 · CA · contact PI
Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene Transcription$515,194
R01 · FY2021 · DK
Targeting a Treg deubiquitinase in antitumor immune therapy$352,184
R01 · FY2021 · CA · contact PI
Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene Transcription$522,708
R01 · FY2020 · DK
Targeting a Treg deubiquitinase in antitumor immune therapy$352,184
R01 · FY2020 · CA · contact PI
Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene Transcription$530,379
R01 · FY2019 · DK
Targeting a Treg deubiquitinase in antitumor immune therapy$341,617
R01 · FY2019 · CA · contact PI
Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene Transcription$551,276
R01 · FY2018 · DK
Targeting a Treg deubiquitinase in antitumor immune therapy$352,184
R01 · FY2018 · CA · contact PI
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus Therapy$338,859
R01 · FY2018 · AR · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$386,250
R01 · FY2017 · AI · contact PI
The roles of Synoviolin in immune tolerance and autoimmunity$379,464
R01 · FY2017 · AI · contact PI
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus Therapy$338,835
R01 · FY2017 · AR · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$386,250
R01 · FY2016 · AI · contact PI
The roles of Synoviolin in immune tolerance and autoimmunity$379,464
R01 · FY2016 · AI · contact PI
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus Therapy$338,789
R01 · FY2016 · AR · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$386,250
R01 · FY2015 · AI · contact PI
The roles of Synoviolin in immune tolerance and autoimmunity$379,464
R01 · FY2015 · AI · contact PI
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus Therapy$338,762
R01 · FY2015 · AR · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$386,250
R01 · FY2014 · AI · contact PI
The roles of Synoviolin in immune tolerance and autoimmunity$379,464
R01 · FY2014 · AI · contact PI
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus Therapy$350,726
R01 · FY2014 · AR · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$121,024
R01 · FY2013 · AI · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$386,250
R56 · FY2012 · AI · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$373,663
R01 · FY2011 · AI · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$377,438
R01 · FY2010 · AI · contact PI
c-Ab1 in the allergic inflammatory lung disease$228,750
R21 · FY2010 · HL · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$180,030
R01 · FY2010 · AI · contact PI
A novel target for type 1 diabetes$97,701
DP2 · FY2010 · DK · contact PI
A novel target for type 1 diabetes$2,288
DP2 · FY2010 · DK · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$381,250
R01 · FY2009 · AI · contact PI
Ubiquitination in arthritis$177,113
R21 · FY2009 · AG · contact PI
c-Ab1 in the allergic inflammatory lung disease$101,826
R21 · FY2009 · HL · contact PI
c-Ab1 in the allergic inflammatory lung disease$85,049
R21 · FY2009 · HL · contact PI
A novel target for type 1 diabetes$2,168,480
DP2 · FY2008 · DK · contact PI
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity$356,425
R01 · FY2008 · AI · contact PI
Ubiquitination in arthritis$146,544
R21 · FY2008 · AG · contact PI
A novel target for type 1 diabetes$116,679
DP2 · FY2008 · DK · contact PI